SARS-CoV-2 ORF7a Antibody - C-terminus - BSA Free
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-05733
Key Product Details
Species Reactivity
SARS-CoV-2
Applications
ELISA, Western Blot
Label
Unconjugated
Antibody Source
Polyclonal Rabbit IgG
Format
BSA Free
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
Synthetic peptide located within the C terminus of SARS-CoV-2 ORF7a.
Clonality
Polyclonal
Host
Rabbit
Isotype
IgG
Applications for SARS-CoV-2 ORF7a Antibody - C-terminus - BSA Free
Application
Recommended Usage
Western Blot
1:500-1000
Formulation, Preparation, and Storage
Purification
Epitope affinity purified
Formulation
PBS, 10% glycerol, pH7.2
Format
BSA Free
Preservative
0.02% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Background: SARS-CoV-2 ORF7a
Similar to its role in SARS-CoV, ORF7a of SARS-CoV-2 is an inhibitor of the host tetherin bone marrow stromal antigen-2 (BST-2) (2, 4). Functionally, ORF7a binds to BST-2, inhibiting its viral restriction activity by blocking glycosylation (2, 4).
References
1. Michel, C. J., Mayenr, C., Poch, O., & Thompson, J. D. (2020). Characterization of accessory genes in coronavirus genomes. Virology journal. https://doi.org/10.1186/s12985-020-01402-1
2. UniProt (P0DTC7)
3. Yoshimoto F. K. (2020). The Proteins of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2 or n-COV19), the Cause of COVID-19. The protein journal. https://doi.org/10.1007/s10930-020-09901-4
4. Taylor, J. K., Coleman, C. M., Postel, S., Sisk, J. M., Bernbaum, J. G., Venkataraman, T., Sundberg, E. J., & Frieman, M. B. (2015). Severe Acute Respiratory Syndrome Coronavirus ORF7a Inhibits Bone Marrow Stromal Antigen 2 Virion Tethering through a Novel Mechanism of Glycosylation Interference. Journal of virology. https://doi.org/10.1128/JVI.02274-15
5. Nelson, C. A., Pekosz, A., Lee, C. A., Diamond, M. S., & Fremont, D. H. (2005). Structure and intracellular targeting of the SARS-coronavirus Orf7a accessory protein. Structure (London, England : 1993). https://doi.org/10.1016/j.str.2004.10.010
Alternate Names
2019-nCoV ORF7a, 2019-nCoV ORF7a Protein, Accessory Protein 7a, COVID-19 Accessory Protein 7a, COVID-19 ORF7a, COVID-19 Protein U122, COVID-19 Protein X4, Human coronavirus ORF7a Protein, ORF7a Protein, Protein U122, Protein X4, SARS-CoV-2 Accessory Protein 7a, SARS-CoV-2 Protein U122, SARS-CoV-2 Protein X4
Gene Symbol
ORF7a
Additional SARS-CoV-2 ORF7a Products
Product Documents for SARS-CoV-2 ORF7a Antibody - C-terminus - BSA Free
Product Specific Notices for SARS-CoV-2 ORF7a Antibody - C-terminus - BSA Free
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...